GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...

UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over ...

GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine ...

GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.

British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to ...

GSK agreed to pay $2.2 billion to 10 plaintiff firms over liability cases related to its discontinued heartburn medicine ...

GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000) ...

The agreement frees the British pharma giant from litigating 93% of the state court cases it faced in the U.S.

GSK has agreed to pay $2.2 billion to settle most of the pending lawsuits that claimed a discontinued version of the Zantac ...

On Wednesday, GSK plc (NYSE:GSK) reached agreements with ten plaintiff firms representing approximately 80,000 Zantac product ...

The deal settles 80,000 US court cases related to allegations that Zantac was contaminated with a suspected carcinogen.

GSK has agreed to pay up to $2.2 billion to settle most pending U.S. state court lawsuits claiming that a discontinued ...